This event is now closed, information is displayed here for information only.
The 2017 ‘Frontiers of Oncology: Haematology’ meeting will be announced in January 2017
but you can pre-register HERE to be advised when the programme is released
A one day meeting held on
Friday 1st July 2016
The Royal College of Physicians, London, UK
Chairs
![]() Director UCL Cancer Institute |
![]() Professor of Haematology UCL Cancer Institute |
From 08.00 | Registration & Coffee |
09.00 | Welcome to the event / setting the scene: the Chairmen |
SESSION 1: BMT | |
09.05 | Introduction from session Chair: Professor Tariq Enver |
09.10 | Targeted radiotherapy – Radio-labelled anti-CD66 antibodies for allograft conditioning Dr Kim Orchard Senior Lecturer, University of Southampton |
09.30 | The influence of reduced intensity conditioning and the future of allograft conditioning regimens Professor Stephen Mackinnon Professor of Haematology, UCL Cancer Institute, London, UK |
09.50 | Progress towards separating GVHD from GVL Professor Ronjon Chakraverty Professor of Cellular Immunotherapy, UCL Cancer Institute, London, UK |
10.10 | Q&A All |
10.25 | Break |
SESSION 2: Lymphoma | |
10.55 | Introduction from session Chair: Professor David Linch |
11.00 | Immune checkpoint therapy for lymphomas (inc. Q&A) Professor Karl Peggs Professor of Stem Cell Transplantation & Immunotherapy, UCL Cancer Institute, London, UK |
11.25 | Recent genetic insights into lymphoma (inc. Q&A) Professor Jude Fitzgibbon Professor of Personalised Cancer Medicine, Bart’s Cancer Institute, London, UK |
11.50 | State of the art therapy for rare lymphoma subtypes (inc. Q&A) Dr Kate Cwynarski Consultant Haematologist UCLH, Honorary Clinical Senior Lecturer UCL Cancer Institute, London, UK |
12.15 | Summary |
12.20 | Lunch |
SESSION 3: ALL / AML | |
13.10 | Introduction from session Chair: Adele Fielding |
13.15 | T ALL – A summary of the genetic landscape and its impact on therapeutic outcome Dr Marc Mansour Professorial Research Fellow, UCL Cancer Institute, London, UK |
13.35 | Novel approaches to treating B-ALL Professor Adele Fielding Professor of Haematology, UCL Cancer Institute, London, UK |
13.55 | Challenges associated with the molecular heterogeneity in AML Professor Rosemary Gale Professor of Haematology, UCL Cancer Institute, London, UK |
14.15 | Q&A |
14.30 | Break |
SESSION 4: Myeloma | |
15.00 | Introduction from session Chair: Professor Kwee Yong |
15.05 | Bromodomain inhibitors explained and their potential utility in the therapy of multiple myeloma Professor Anastasios Karadimitris Professor of Haematology, Imperial College London, UK |
15.30 | Early clinical development of new treatments in myeloma Dr Rakesh Popat Consultant Haematologist at UCLH, Honorary Clinical Senior Lecturer at the UCL Cancer Institute, London, UK |
15.55 | A redefinition of myeloma Dr Jenny Bird Consultant Haematologist, University Hospitals Bristol, UK |
16.30 | Summary & Close |
This meeting is organised by:
and endorsed and supported by:
The Frontiers of Oncology 2019 meetings are supported by the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.